Treatment advances have not improved the early death rate in acute promyelocytic leukemia.
about
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisA review of arsenic trioxide and acute promyelocytic leukemiaA Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsHistory of acute promyelocytic leukemia: a tale of endless revolutionAcute myeloid leukemia in the real world: why population-based registries are needed.Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in CaliforniaEarly Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3 Isoform, FLT3-ITD Mutation, and Elevated WT1 Level.Clinical characteristics of acute promyelocytic leukemia manifesting as early death.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Management of elderly patients with acute promyelocytic leukemia: progress and problems.Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.Current standard treatment of adult acute promyelocytic leukaemia.Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.Current management of newly diagnosed acute promyelocytic leukemia.Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia.Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia.Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death
P2860
Q27336142-D6F99FD4-6248-4D9D-910B-37737D39765FQ28087768-4C392AE1-95BD-41BD-ABC5-070E70A497CBQ34305899-8B7A370E-8F31-44BD-86A4-F3D116041690Q35640780-6703845C-A39B-4130-B093-273B19D640E9Q35980291-CB67C91C-22BA-4E26-9967-90D6CE75EB9DQ36253767-AABD799E-F1E8-4090-B31F-1D0E82F1A4B1Q37044400-085DAE69-7891-49BF-BAE1-180436AD7272Q37559549-CD9C81F9-D710-4EFC-913D-769202985E5AQ37712353-F1C46097-E92D-4AE8-8B29-251DBC4B1BC3Q38108471-C165FA4C-983F-4331-9004-137161194259Q38139992-9428BA43-42C6-4710-B955-9F493E25BD73Q38674575-E249BA90-FEA3-4F22-B11C-A9844C9D6646Q38752325-418AF201-95A4-44C2-AFF1-C9CA4645ED10Q38809825-2B83349C-74AA-4AA0-9C81-29A8D439F1AFQ38907861-1CC35D85-FD6B-4624-913C-7C4F3E5BD341Q41265804-C97AB686-ECCD-45E8-A019-565C95E98C8EQ41662169-3B218715-0E63-4970-949D-25C21B3ABF90Q44693583-3BD49658-C6E0-43DF-A87E-474C1B1F44FAQ45021199-D0728EEC-5097-47F8-9E62-8A6E6693698AQ47229461-93DC332E-42C8-47BF-AE9C-2E8355ACF7AAQ47734635-057B994B-AD76-49D8-A0A5-CAFCF6B86AB3Q47757780-115441B1-5F6C-4FC6-849B-B2E4638A40CAQ48200551-DAE06F0A-A685-4B99-8CAF-FB3A0B055F37Q48264212-A690FEF9-927D-4BF6-9C0E-D0F278844BD5Q48340234-804177A3-47C7-48A9-BCDD-8DA59829C593Q50972621-9651C16A-E11F-4EF3-AA27-4824AD4BC414Q51759775-312EFCA2-25F5-4128-BF97-50B9A9B17FA6Q57074270-D644CBBD-3CB1-4E6F-978E-EE0401382670
P2860
Treatment advances have not improved the early death rate in acute promyelocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment advances have not im ...... acute promyelocytic leukemia.
@ast
Treatment advances have not im ...... acute promyelocytic leukemia.
@en
Treatment advances have not im ...... acute promyelocytic leukemia.
@nl
type
label
Treatment advances have not im ...... acute promyelocytic leukemia.
@ast
Treatment advances have not im ...... acute promyelocytic leukemia.
@en
Treatment advances have not im ...... acute promyelocytic leukemia.
@nl
prefLabel
Treatment advances have not im ...... acute promyelocytic leukemia.
@ast
Treatment advances have not im ...... acute promyelocytic leukemia.
@en
Treatment advances have not im ...... acute promyelocytic leukemia.
@nl
P2093
P2860
P1433
P1476
Treatment advances have not im ...... acute promyelocytic leukemia.
@en
P2093
Ash A Alizadeh
Bruno C Medeiros
Holbrook E Kohrt
James Scott McClellan
Jason R Gotlib
Ravindra Majeti
Steven Coutre
P2860
P304
P356
10.3324/HAEMATOL.2011.046490
P577
2011-10-11T00:00:00Z